CVNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

CapsoVision, Inc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$6.67+0.14 (+2.14%)

Close on Oct 19, 2026

Market cap: $333.08M
P/E (TTM): –
Dividend yield: –

CapsoVision, Inc balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Receivables	2.50	2.00	–
Inventory	2.99	2.63	–
Prepaid Expenses & Other	1.07	0.90	–
Other Current Assets	0.45	0.26	–
Total Current Assets	17	15	–
Property, Plant & Equipment	0.61	0.72	–
Accumulated Depreciation	-0.58	-0.36	–
Machinery & Equipment	0.93	0.82	–
Operating Lease Right-of-Use Assets	0.84	1.20	–
Other Long-Term Assets	0.04	0.04	–
Total Assets	18	17	–
Accounts Payable	1.14	0.75	–
Accrued Expenses	2.70	0.57	–
Current Portion of Leases	0.41	0.35	–
Deferred Revenue (Current)	0.18	0.13	0.10
Other Current Liabilities	0.52	0.14	–
Total Current Liabilities	4.43	1.80	–
Long-Term Leases	0.48	0.89	–
Operating Lease Liabilities	0.89	1.24	–
Total Liabilities	4.90	2.69	–
Preferred Stock	0	–	–
Common Stock	0.05	0.00	–
Additional Paid-In Capital	169	0.84	–
Retained Earnings	-156	-130	–
Shareholders' Equity	13	-130	-110
Total Equity	13	-130	-110
Total Liabilities & Equity	18	17	–
Shares Outstanding(shares)	47	2.09	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 50.9%
Operating margin: -217.1%
Net margin: -214.7%
Return on equity, FY2025: 43.6%

Financial strength

Current ratio: 3.35
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: 23.98
Price to book: 25.30
Dividend yield: –